Show simple item record

dc.contributor.authorChristiansen, D
dc.contributor.authorEarnest-Silveira, L
dc.contributor.authorChua, B
dc.contributor.authorMeuleman, P
dc.contributor.authorBoo, I
dc.contributor.authorGrubor-Bauk, B
dc.contributor.authorJackson, DC
dc.contributor.authorKeck, ZY
dc.contributor.authorFoung, SKH
dc.contributor.authorDrummer, HE
dc.contributor.authorGowans, EJ
dc.contributor.authorTorresi, J
dc.date.accessioned2020-12-17T03:25:35Z
dc.date.available2020-12-17T03:25:35Z
dc.date.issued2018-04-24
dc.identifierpii: 10.1038/s41598-018-24762-9
dc.identifier.citationChristiansen, D., Earnest-Silveira, L., Chua, B., Meuleman, P., Boo, I., Grubor-Bauk, B., Jackson, D. C., Keck, Z. Y., Foung, S. K. H., Drummer, H. E., Gowans, E. J. & Torresi, J. (2018). Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. SCIENTIFIC REPORTS, 8 (1), https://doi.org/10.1038/s41598-018-24762-9.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11343/254880
dc.description.abstractThe significant public health problem of Hepatitis C virus (HCV) has been partially addressed with the advent of directly acting antiviral agents (DAAs). However, the development of an effective preventative vaccine would have a significant impact on HCV incidence and would represent a major advance towards controlling and possibly eradicating HCV globally. We previously reported a genotype 1a HCV viral-like particle (VLP) vaccine that produced neutralizing antibodies (NAb) and T cell responses to HCV. To advance this approach, we produced a quadrivalent genotype 1a/1b/2a/3a HCV VLP vaccine to produce broader immune responses. We show that this quadrivalent vaccine produces antibody and NAb responses together with strong T and B cell responses in vaccinated mice. Moreover, selective neutralizing human monoclonal antibodies (HuMAbs) targeting conserved antigenic domain B and D epitopes of the E2 protein bound strongly to the HCV VLPs, suggesting that these critical epitopes are expressed on the surface of the particles. Our findings demonstrate that a quadrivalent HCV VLP based vaccine induces broad humoral and cellular immune responses that will be necessary for protection against HCV. Such a vaccine could provide a substantial addition to highly active antiviral drugs in eliminating HCV.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleImmunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine
dc.typeJournal Article
dc.identifier.doi10.1038/s41598-018-24762-9
melbourne.affiliation.departmentMicrobiology and Immunology
melbourne.source.titleScientific Reports
melbourne.source.volume8
melbourne.source.issue1
melbourne.identifier.nhmrc1060436
melbourne.identifier.nhmrc1126379
dc.rights.licenseCC BY
melbourne.elementsid1325541
melbourne.contributor.authorTorresi, Joseph
melbourne.contributor.authorChristiansen, Dale
melbourne.contributor.authorEarnest, Linda
melbourne.contributor.authorJackson, David
melbourne.contributor.authorChua, Brendon
melbourne.contributor.authorDrummer, Heidi
dc.identifier.eissn2045-2322
melbourne.identifier.fundernameidNHMRC, 1060436
melbourne.identifier.fundernameidNHMRC, 1126379
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record